ANTURANE
LOE ApproachingNDAORALTABLET
Approved
May 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTURANE is an oral small-molecule tablet approved in 1959 by Novartis under NDA status. The drug's specific indication, mechanism of action, and pharmacologic class are not publicly detailed in available records. It is a legacy product nearing loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), indicating a mature brand team focused on retention and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ANTURANE offers limited career growth opportunities with zero linked job postings currently available. Working on this product involves managing decline, optimizing cost structure, and preparing transition strategies rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on ANTURANE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.